Cell line · CVCL_3326
Pfeiffer
Cancer cell line, Homo sapiens. Diffuse large B-cell lymphoma germinal center B-cell type. 32 papers.
4 sourcescell-lines-2026-11-14-0.1.0
Download JSON
Cite this record
ConductScience Library. Pfeiffer. Cell lines, record CVCL_3326. Release cell-lines-2026-11-14-0.1.0, 14 Nov 2026. https://conductscience.org/library/cell-lines/CVCL_3326
On this page
Cell line
As Cellosaurus gives it.
- Name
- Pfeiffer
- Accession
- CVCL_3326
- RRID
- RRID:CVCL_3326
- Synonyms
- PFEIFFER
- Species
- Homo sapiens (Human)
- Sex
- Male
- Age at sampling
- Adult
- Category
- Cancer cell line
- Diseases
- Diffuse large B-cell lymphoma germinal center B-cell type (NCIt C36080); Diffuse large B-cell lymphoma (ORDO Orphanet_544)
- Derived from
- Pleural effusion (in situ)
- Cell type
- B-cell
- Entry created
- 2012-04-04
- Entry updated
- 2025-04-10
Source Cellosaurus
Problems0
Cellosaurus records no problem for this cell line.
None in this release.
Papers32
| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Functional genomics and proteomics identify Folate Carrier SLC19A1 as a predictor of pralatrexate sensitivity in diverse T-cell lymphoma models. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy. | Front Immunol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Multi-modal analysis reveals tumor and immune features distinguishing EBV-positive and EBV-negative post-transplant lymphoproliferative disorders. | Cell Rep Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of bromodomain and extra-terminal proteins targets constitutively active NFκB and STAT signaling in lymphoma and influences the expression of the antiapoptotic proteins BCL2A1 and c-MYC. | Cell Commun Signal | 2024 | Its Methods give the RRID and name the line | PubMed | |
| GNAS knockout potentiates HDAC3 inhibition through viral mimicry-related interferon responses in lymphoma. | Leukemia | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Novel Spirocyclic Dimer, SpiD3, Targets Chronic Lymphocytic Leukemia Survival Pathways with Potent Preclinical Effects. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| 4'-Ethynyl-2'-Deoxycytidine (EdC) Preferentially Targets Lymphoma and Leukemia Subtypes by Inducing Replicative Stress. | Mol Cancer Ther | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. | Nat Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| IOA-244 is a Non-ATP-competitive, Highly Selective, Tolerable PI3K Delta Inhibitor That Targets Solid Tumors and Breaks Immune Tolerance. | Cancer Res Commun | 2023 | Its Methods give the RRID and name the line | PubMed | |
| Mitochondrial pyruvate supports lymphoma proliferation by fueling a glutamate pyruvate transaminase 2-dependent glutaminolysis pathway. | Sci Adv | 2022 | Its Methods give the RRID and name the line | PubMed |
1 to 10 of 32
See all 32 papersRelatives1
| Relation | Cell line | Accession | Problem |
|---|---|---|---|
| Derived from it | MA-1 [Human contaminated lymphoma] | CVCL_M665 | Has a recorded problem |
Source Cell lines
Cell banks1
| Cell bank | Catalog number | Status |
|---|---|---|
| ATCC | CRL-2632 |
Source ATCC
Data dates
The date of each source this release read.
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this cell line from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_3326
GET https://conductscience.org/api/cell-lines/v1/CVCL_3326/papers?page=2